Canada Markets close in 1 hr 38 mins

Celldex Therapeutics, Inc. (CLDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
42.52-1.30 (-2.97%)
As of 4:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close43.82
Open43.61
Bid39.00 x 1400
Ask55.00 x 900
Day's Range42.22 - 45.25
52 Week Range15.37 - 57.20
Volume374,947
Avg. Volume434,379
Market Cap1.684B
Beta (5Y Monthly)3.05
PE Ratio (TTM)N/A
EPS (TTM)-2.02
Earnings DateNov. 03, 2021 - Nov. 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est62.25
  • GlobeNewswire

    Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021

    HAMPTON, N.J., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. These data were presented in a poster session as part of the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021). The data show CDX-585 effectively combines the blockade of ILT4 and PD-1 into one

  • GlobeNewswire

    Celldex to Participate in Upcoming Investor Conferences

    HAMPTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following virtual investor conferences in November: Guggenheim 3rd Annual Healthcare Talks Neuro/Immunology Conference on Tuesday, November 16, 2021 at 10:20 a.m. ETJefferies London Healthcare Conference available on-demand beginning Thursday, November 18, 2021 at 3:00 a.m. ET / 8:00 a.m. GMTEvercore ISI 4th Annual HealthCONx Conferen

  • Zacks

    Celldex Therapeutics (CLDX) Reports Q3 Loss, Lags Revenue Estimates

    Celldex (CLDX) delivered earnings and revenue surprises of -11.43% and -91.02%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?